Mary Elizabeth Strek to Disease Progression
This is a "connection" page, showing publications Mary Elizabeth Strek has written about Disease Progression.
Connection Strength
0.903
-
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease. Eur Respir J. 2023 07; 62(1).
Score: 0.146
-
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. Am J Respir Crit Care Med. 2021 07 15; 204(2):197-208.
Score: 0.127
-
Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest. 2016 Dec; 150(6):1371-1386.
Score: 0.090
-
Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011 Nov; 140(5):1292-1299.
Score: 0.063
-
ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease. Eur Respir J. 2026 Jan; 67(1).
Score: 0.043
-
Treatable traits in interstitial lung disease: opportunities and challenges. Respir Med. 2025 Nov; 248:108353.
Score: 0.042
-
Quantitative CT Scan Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease. Chest. 2025 May; 167(5):1428-1439.
Score: 0.040
-
Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary Fibrosis. Chest. 2024 03; 165(3):621-631.
Score: 0.037
-
Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31; 24(1):141.
Score: 0.036
-
Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J. 2022 06; 59(6).
Score: 0.034
-
Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022 09; 162(3):603-613.
Score: 0.033
-
High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Sci Rep. 2021 11 24; 11(1):22821.
Score: 0.033
-
Detection and Early Referral of Patients With Interstitial Lung Abnormalities: An Expert Survey Initiative. Chest. 2022 02; 161(2):470-482.
Score: 0.032
-
Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. Am J Respir Crit Care Med. 2020 01 15; 201(2):250-253.
Score: 0.029
-
Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Ann Am Thorac Soc. 2019 05; 16(5):580-588.
Score: 0.027
-
Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J. 2019 04; 53(4).
Score: 0.027
-
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018 Dec 31; 27(150).
Score: 0.027
-
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
Score: 0.019
-
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 07; 158(9):641-9.
Score: 0.018